Enhancement of an Artificial Lung for Ambulatory Respiratory Support

增强人工肺的动态呼吸支持

• 批准号: 10174997
• 负责人: Bartley P GriffIth
• 金额: $ 74.57万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-05 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10174997
• 关键词: Acute; Acute Disease; Acute respiratory failure; Air; Algorithms; Animal Experiments; Animals; Area; Biocompatible Materials; Biological; Blood; Blood gas; Carbon Dioxide; Chronic; Chronic lung disease; Destinations; Development; Devices; Electromagnetics; Evaluation; Excision; Exercise; Extracorporeal Membrane Oxygenation; Fuzzy Logic; Gases; Goals; Healthcare; Hemolysis; Hospitals; Hour; In Vitro; Injury; Legal patent; Liquid substance; Lung; Lung diseases; Measurement; Mechanical ventilation; Mechanics; Membrane; National Heart, Lung, and Blood Institute; Oxygen; Oxyhemoglobin; Patients; Performance; Physiological; Pump; Pump lung; Safety; Self-Help Devices; Software Validation; Source; Sterilization; Surface; System; Technology; Testing; Toxic effect; Transplantation; Validation; Venous; Weight; artificial lung; base; biomaterial compatibility; commercialization; design; exhaust; healing; improved; in vivo; light weight; manufacturability; manufacturing process; multidisciplinary; new technology; novel; portability; pre-clinical; regenerative therapy; respiratory; respiratory assist; response; sheep model; sterility testing

Acute and chronic end-stage lung diseases (ESLD) are increasing healthcare problems. Currently, when mechanical ventilation fails only extracorporeal membrane oxygenation (ECMO) with components designed and qualified for a few hours is available. Current ECMO systems are often associated with serious complications and generally are restricted to bedside use. A wearable, biocompatible integrated pump-lung would offer significant advantages to patients over existing options. Such a device would pose a prolonged ambulatory platform for natural lung healing from acute injury, a bridge to transplant or destination therapy, or for novel lung regenerative therapies. With support from the NHLBI, we have made remarkable progress in development of a wearable artificial pump-lung system (APLS) for ambulatory respiratory support. The goal of this renewal application is to develop a new class of gas exchange device with adaptive physiologic control for a wearable artificial lung system. We propose to develop unique strategies to reduce the sizes of gas exchanger devices and associated drive consoles and to provide adaptive respiratory support to ambulating ECMO patients. Three specific aims of the proposal are: (1) to develop a small-sized and multifunctional membrane respiratory assist device (MRAD) for ECMO therapy in the ambulatory setting. The novel MRAD will include a dual chamber gas exchanger (DCGE) for blood and gas flows with an integrated centrifugal pump; (2) to develop a lightweight console for the MRAD with auto-adaptive control based on the gas exchange demand of an ambulating patient. The portable console will be less than 20 lbs and can be placed into a backpack; and (3) to conduct in-vitro regulatory qualification tests and chronic (30-day) in-vivo animal experiments to assess the long-term function, biocompatibility, and durability of the MRAD and its biologic effect on the animal. The efficiency of the new gas exchange device will reduce its size and its console by near 30%. The reduced console size and weight will reduce its burden to the user and will permit its configuration into a backpack design as well as a small roller case. Completion of aims will redefine the technology appropriate for broadened use of ambulatory ECMO and for its out-of-hospital use.

急性和慢性终末期肺病（ESLD）正在加剧医疗保健问题。目前，当 机械通气仅对采用设计组件的体外膜肺氧合 (ECMO) 失败 并且合格的几个小时是可用的。当前的 ECMO 系统通常与严重的 并发症，并且通常仅限于床边使用。可穿戴、生物相容性集成泵肺 与现有的选择相比，将为患者提供显着的优势。这种装置会造成长时间的 用于急性损伤肺部自然愈合的流动平台，移植或目的地治疗的桥梁，或 用于新型肺再生疗法。在 NHLBI 的支持下，我们在以下方面取得了显着进展： 开发用于动态呼吸支持的可穿戴人工泵肺系统（APLS）。目标是 这项更新应用旨在开发一种具有自适应生理控制功能的新型气体交换装置 可穿戴式人工肺系统。 我们建议制定独特的策略来减小气体交换设备和相关驱动器的尺寸 控制台并为移动 ECMO 患者提供适应性呼吸支持。三大具体目标 提案是：（1）开发小型多功能膜式呼吸辅助装置（MRAD） 门诊环境下的 ECMO 治疗。新型 MRAD 将包括双室气体交换器 (DCGE) 使用集成离心泵进行血液和气体流动； (2) 为MRAD开发轻量级控制台 根据移动患者的气体交换需求进行自适应控制。便携式控制台 重量小于 20 磅，可放入背包中； (3) 进行体外监管资质 测试和长期（30天）体内动物实验，以评估长期功能、生物相容性和 MRAD 的耐久性及其对动物的生物学影响。 新型气体交换装置的效率将使其尺寸及其控制台缩小近30%。减少的 控制台的尺寸和重量将减轻用户的负担，并允许将其配置到背包中 设计以及一个小滚轮箱。目标的完成将重新定义适合的技术 扩大了门诊 ECMO 的使用及其院外使用。